Patents by Inventor MICHELLE RENEE GARNSEY

MICHELLE RENEE GARNSEY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Papain-like protease (PLpro) inhibitors
    Publication number: 20240245673
    Abstract: The invention relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of Formula (I) may inhibit the activity of papain-like protease (PLpro) and may be useful in the treatment of viral infections, in particular viral infections associated with PLpro activity and/or expression such as coronaviruses infections.
    Type: Application
    Filed: December 7, 2023
    Publication date: July 25, 2024
    Applicant: Pfizer Inc.
    Inventors: James Matthew Frick, Michelle Renee Garnsey, Brian Stephen Gerstenberger, Xinjun Hou, Magdalena Korczynska, Alpha Albert Lee, Luong Tien Nguyen, Usa Reilly, Matthew Christopher Robinson, Alexandria Paige Taylor, Thomas Reynold Vargo, Lei Zhang
  • HSD17B13 Inhibitors and/or Degraders
    Publication number: 20240238425
    Abstract: Described herein are 3-fluoro-4-hydroxybenzamide-containing inhibitors and/or degraders, and pharmaceutical compositions containing 3-fluoro-hydroxybenzamide-containing inhibitors and/or degraders. In some embodiments, the 3-fluoro-4-hydroxybenzamide-containing compounds of the disclosure can be used to treat a condition, for example, nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Type: Application
    Filed: December 15, 2023
    Publication date: July 18, 2024
    Applicant: Pfizer Inc.
    Inventors: Jan Antoinette Cusi Romero Adams, Yotam Ashkenazi, Matthew Frank Brown, Jason Kenneth Dutra, Michelle Renee Garnsey, Xinjun Hou, Jisun Lee, Yajing Lian, Deane Milford Nason, II, Steven Victor O'Neil, Amanda Brooke Pecora, Alistair Dean Richardson, Matthew Forrest Sammons, Yang Wang, Ann Sorrentino Wright, Jun Xiao, Lei Zhang, Liying Zhang
  • HSD17B13 INHIBITORS AND/OR DEGRADERS
    Publication number: 20240150334
    Abstract: Described herein are compounds of Formula I, wherein the variables are defined herein, their use as HSD17B13 inhibitors and/or degraders, pharmaceutical compositions containing such compounds and their use to treat, for example, NAFLD and NASH.
    Type: Application
    Filed: October 6, 2023
    Publication date: May 9, 2024
    Applicant: Pfizer Inc.
    Inventors: Jan Antoinette Cusi Romero Adams, Bruce Michael Bechle, Jason Kenneth Dutra, Michelle Renee Garnsey, Xinjun Hou, Jisun Lee, Deane Milford Nason, II, Steven Victor O'Neil, Danica Antonia Rankic, Yang Wang, Ann Sorrentino Wright, Lei Zhang, Liying Zhang, David James Edmonds
  • METHODS FOR ANTAGONIZING A MELANOCORTIN 4 RECEPTOR
    Publication number: 20230174532
    Abstract: Described herein are methods of treating MC4R-related conditions, diseases, or disorders by administering compounds of Formula I: or their pharmaceutically acceptable salts, wherein R1, R2, R3, X1, Y1, Y2, Y3, Y4 and Y5 are defined herein. Such conditions, diseases, or disorders include cachexia, anorexia, or anorexia nervosa.
    Type: Application
    Filed: January 31, 2023
    Publication date: June 8, 2023
    Applicant: Pfizer Inc.
    Inventors: Christopher Ryan BUTLER, Michelle Renee GARNSEY, Kevin Alexander OGILVIE, Jana POLIVKOVA, Matthew Forrest SAMMONS, Aaron Christopher SMITH, Qingyi Yang
  • Melanocortin 4 receptor antagonists and uses thereof
    Patent number: 11643412
    Abstract: Described herein are compounds of Formula I: and their pharmaceutically acceptable salts, wherein R1, R2, R3, X1, Y1, Y2, Y3, Y4 and Y5 are defined herein; their use as MC4R antagonists; pharmaceutical compositions containing such compounds and salts; the use of such compounds and salts to treat, for example, cachexia, anorexia, or anorexia nervosa; and intermediates and processes for preparing such compounds and salts.
    Type: Grant
    Filed: June 8, 2021
    Date of Patent: May 9, 2023
    Assignee: Pfizer Inc.
    Inventors: Christopher Ryan Butler, Michelle Renee Garnsey, Kevin Alexander Ogilvie, Jana Polivkova, Matthew Forrest Sammons, Aaron Christopher Smith, Qingyi Yang
  • MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF
    Publication number: 20230019853
    Abstract: Described herein are compounds of Formula I: and their pharmaceutically acceptable salts, wherein R1, R2, R3, X1, Y1, Y2, Y3, Y4 and Y5 are defined herein; their use as MC4R antagonists; pharmaceutical compositions containing such compounds and salts; the use of such compounds and salts to treat, for example, cachexia, anorexia, or anorexia nervosa; and intermediates and processes for preparing such compounds and salts.
    Type: Application
    Filed: June 8, 2021
    Publication date: January 19, 2023
    Applicant: Pfizer Inc.
    Inventors: Christopher Ryan Butler, Michelle Renee Garnsey, Kevin Alexander Ogilvie, Jana Polivkova, Matthew Forrest Sammons, Aaron Christopher Smith, Qingyi Yang
  • Diacylglycerol acyl transferase 2 inhibitor
    Patent number: 11471458
    Abstract: Described herein are compounds of Formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are defined herein, their use as diacylglycerol acyltransferase 2 (DGAT2) inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, NASH.
    Type: Grant
    Filed: October 5, 2020
    Date of Patent: October 18, 2022
    Assignee: Pfizer Inc.
    Inventors: David James Edmonds, Kevin James Filipski, Kentaro Futatsugi, Michelle Renee Garnsey, Jack Chang Hung Lee, Daniel Jonathan Smaltz
  • Imidazo[4,5-C]quinoline derivatives as LRRK2 inhibitors
    Patent number: 11312713
    Abstract: The present invention provides novel imidazo[4,5-c]quinoline derivatives of Formula (I), and the pharmaceutically acceptable salts thereof I wherein R1, R2 and R3 are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: April 26, 2022
    Assignee: Pfizer Inc.
    Inventors: Michael Aaron Brodney, Thomas Allen Chappie, Jinshan Michael Chen, Jotham Wadsworth Coe, Karen Jean Coffman, Paul Galatsis, Michelle Renee Garnsey, Christopher John Helal, Jaclyn Louise Henderson, Bethany Lyn Kormos, Ravi G. Kurumbail, Luis Angel Martinez-Alsina, Martin Youngjin Pettersson, Matthew Richard Reese, Colin Richard Rose, Antonia Friederike Stepan, Patrick Robert Verhoest, Travis T. Wager, Joseph Scott Warmus, Yuan Zhang
  • NOVEL IMIDAZO[4,5-C]QUINOLINE DERIVATIVES AS LRRK2 INHIBITORS
    Publication number: 20210355117
    Abstract: The present invention provides novel imidazo[4,5-c]quinoline derivatives of Formula (I), and the pharmaceutically acceptable salts thereof I wherein R1, R2 and R3 are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.
    Type: Application
    Filed: March 6, 2018
    Publication date: November 18, 2021
    Inventors: Michael Aaron BRODNEY, Thomas Allen CHAPPIE, Jinshan Michael CHEN, Jotham Wadsworth COE, Karen Jean COFFMAN, Paul GALATSIS, Michelle Renee GARNSEY, Christopher John HELAL, Jaclyn Louise Henderson, Bethany Lyn KORMOS, Ravi G. KURUMBAIL, Luis Angel MARTINEZ-ALSINA, Martin Youngjin PETTERSSON, Matthew Richard REESE, Colin Richard ROSE, Antonia Friederike STEPAN, Patrick Robert VERHOEST, Travis T. WAGER, Joseph Scott WARMUS, Yuan ZHANG
  • Cyclic substituted imidazo[4,5-c]quinoline derivatives
    Patent number: 11161844
    Abstract: The present invention provides novel cyclic substituted imidazo[4,5-c]quinoline derivatives of Formula (I), and the pharmaceutically acceptable salts thereof; wherein R1, R2, R4, R5, R6, X and Z are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: November 2, 2021
    Assignee: PFIZER INC.
    Inventors: Thomas Allen Chappie, Paul Galatsis, Michelle Renee Garnsey, Christopher John Helal, Jaclyn Louise Henderson, Bethany Lyn Kormos, Ravi G. Kurumbail, Luis Angel Martinez-Alsina, Martin Youngjin Pettersson, Antonia Friederike Stepan, Travis T. Wager
  • Diacylglycerol acyl transferase 2 inhibitor
    Patent number: 11065249
    Abstract: Described herein are compounds of Formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are defined herein, their use as diacylglycerol acyltransferase 2 (DGAT2) inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, NASH.
    Type: Grant
    Filed: November 5, 2020
    Date of Patent: July 20, 2021
    Assignee: Pfizer Inc.
    Inventors: David James Edmonds, Kevin James Filipski, Kentaro Futatsugi, Michelle Renee Garnsey, Jack Chang Hung Lee, Daniel Jonathan Smaltz
  • DIACYLGLYCEROL ACYL TRANSFERASE 2 INHIBITOR
    Publication number: 20210100796
    Abstract: Described herein are compounds of Formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are defined herein, their use as diacylglycerol acyltransferase 2 (DGAT2) inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, NASH.
    Type: Application
    Filed: October 5, 2020
    Publication date: April 8, 2021
    Applicant: Pfizer Inc.
    Inventors: David James Edmonds, Kevin James Filipski, Kentaro Futatsugi, Michelle Renee Garnsey, Jack Chang Hung Lee, Daniel Jonathan Smaltz
  • DIACYLGLYCEROL ACYL TRANSFERASE 2 INHIBITOR
    Publication number: 20210100798
    Abstract: Described herein are compounds of Formula (1) wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are defined herein, their use as diacylglycerol acyltransferase 2 (DGAT2) inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, NASH.
    Type: Application
    Filed: November 5, 2020
    Publication date: April 8, 2021
    Applicant: Pfizer Inc.
    Inventors: David James Edmonds, Kevin James Filipski, Kentaro Futatsugi, Michelle Renee Garnsey, Jack Chang Hung Lee, Daniel Jonathan Smaltz
  • CYCLIC SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE DERIVATIVES
    Publication number: 20200039977
    Abstract: The present invention provides novel cyclic substituted imidazo[4,5-c]quinoline derivatives of Formula (I), and the pharmaceutically acceptable salts thereof, wherein R1, R2, R4, R5, R6, X and Z are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.
    Type: Application
    Filed: March 1, 2018
    Publication date: February 6, 2020
    Inventors: Thomas Allen Chappie, Paul Galatsis, Michelle Renee Garnsey, Christopher John Helal, Jaclyn Louise Henderson, Bethany Lyn Kormos, Ravi G. Kurumbail, Luis Angel Martinez-Alsina, Martin Youngjin Pettersson, Antonia Friederike Stepan, Travis T. Wager
  • Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors
    Patent number: 10039753
    Abstract: The present invention provides novel imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives of Formula (I), and the pharmaceutically acceptable salts thereof wherein R1, R1a, R1b, R2, R4, R5, R6, X and Z are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula (I) and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.
    Type: Grant
    Filed: September 12, 2016
    Date of Patent: August 7, 2018
    Assignee: Pfizer Inc.
    Inventors: Karen Jean Coffman, Paul Galatsis, Michelle Renee Garnsey, Jaclyn Louise Henderson, Bethany Lyn Kormos, Ravi G. Kurumbail, Martin Youngjin Pettersson, Matthew Richard Reese, Antonia Friederike Stepan, Patrick Robert Verhoest, Travis T. Wager
  • Novel Imidazo[4,5-c]Quinoline And Imidazo[4,5-c][1,5]Naphthyridine Derivatives As LRRK2 Inhibitors
    Publication number: 20170073343
    Abstract: The present invention provides novel imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives of Formula (I), and the pharmaceutically acceptable salts thereof wherein R1, R1a, R1b, R2, R4, R5, R6, X and Z are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula (I) and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.
    Type: Application
    Filed: September 12, 2016
    Publication date: March 16, 2017
    Applicant: Pfizer Inc.
    Inventors: Paul Galatsis, Jaclyn Louise Henderson, Bethany Lyn Kormos, Ravi G. Kurumbail, Matthew Richard Reese, Antonia Friederike Stepan, Patrick Robert Verhoest, Travis T. Wager, Martin Youngjin Pettersson, Michelle Renee Garnsey
  • PYRIDINE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
    Publication number: 20160016907
    Abstract: The present invention provides, in part, compounds of Formula I: N-oxides thereof, and pharmaceutically acceptable salts of the compounds or N-oxides; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M1-mediated (or M1-associated) disorders including, e.g., Alzheimer's disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.
    Type: Application
    Filed: July 15, 2015
    Publication date: January 21, 2016
    Applicant: PFIZER INC.
    Inventors: MICHAEL AARON BRODNEY, JENNIFER ELIZABETH DAVOREN, MICHELLE RENEE GARNSEY, LEI ZHANG, STEVEN VICTOR O'NEIL